-
公开(公告)号：WO2021030602A1
公开(公告)日：2021-02-18
申请号：PCT/US2020/046202
申请日：2020-08-13
Applicant: AMGEN INC.
Inventor： BATES, Darren L. , SOHN, Sue J. , CATTERALL, Hannah , WANG, Zhulun
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc fusion molecules that preferentially expand and activate cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.
-
2.发明申请METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS 审中-公开使用结合蛋白治疗或改善代谢性疾病的方法用于胃泌受体肽受体（GIPR）与GLP-1激动剂组合
公开(公告)号：WO2017112824A2
公开(公告)日：2017-06-29
申请号：PCT/US2016/068138
申请日：2016-12-21
Applicant: AMGEN INC.
Inventor： YIE, Junming , SHI, Donghui , LLOYD, David J. , WANG, Jinghong , SIVITS, JR., Glenn N. , VENIANT-ELLISON, Murielle M. , KOMOROWSKI, Renee , AGRAWAL, Neeraj , BATES, Darren L. , CLAVETTE, Brandon C. P. , FOLTZ, Ian N. , HO, Shu-yin , MURAWSKY, Christopher , MIN, Xiaoshan , WANG, Zhulun
IPC: C07K16/28
CPC classification number: C07K16/2869 , A61K9/0019 , A61K38/1703 , A61K38/26 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2299/00 , C07K2317/21 , C07K2317/32 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
Abstract translation: 提供了使用对GIPR多肽特异的抗原结合蛋白治疗代谢疾病和病症的方法。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，葡萄糖水平升高，胰岛素水平升高和糖尿病性肾病。 在某些实施方案中，抗原结合蛋白与GLP-1受体激动剂联合给药。
-
公开(公告)号：WO2014089335A2
公开(公告)日：2014-06-12
申请号：PCT/US2013/073382
申请日：2013-12-05
Applicant: AMGEN INC.
Inventor： ARMITAGE, Richard J. , BLAKE, Michelle , FANSLOW, III, William C. , O'NEILL, Jason Charles , KANNAN, Gunasekaran , XU, Jiangchun , TOMETSKO, Mark Edward , WANG, Zhulun , SUDOM, Athena
CPC classification number: C07K16/2878 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K2039/505 , A61N5/10 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
Abstract translation: 本发明涉及BCMA（B细胞成熟抗原）抗原结合蛋白，例如抗体，编码所述抗原结合蛋白的多核苷酸序列，以及用于诊断和治疗疾病的组合物和方法。 本发明还涉及BCMA抗体药物共轭物及其用途。
-
公开(公告)号：WO2022040466A1
公开(公告)日：2022-02-24
申请号：PCT/US2021/046770
申请日：2021-08-19
Applicant: AMGEN INC.
Inventor： GARCES, Fernando , WANG, Zhulun
IPC: C07K16/46
Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new placement for a non-canonical disulfide bond and as such the generation of an asymmetric cysteine interface between two Fabs present in the same molecule which will further enable the production of multispecifics.
-
公开(公告)号：WO2021102049A1
公开(公告)日：2021-05-27
申请号：PCT/US2020/061124
申请日：2020-11-18
Applicant: AMGEN INC.
Inventor： GARCES, Fernando , WANG, Zhulun
Abstract: The present invention relates to novel multispecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the multispecific antigen binding proteins as well as methods for producing them are also disclosed.
-
Patent Agency Ranking
公开(公告)号：WO2013173761A2
公开(公告)日：2013-11-21
申请号：PCT/US2013/041656
申请日：2013-05-17
Applicant: AMGEN INC.
Inventor： SMITH, Dirk E. , FOLTZ, Ian , KING, Chadwick T. , LIM, Ai Ching , CLARK, Rutilio , COMEAU, Michael R. , KETCHEM, Randal R. , SHI, Donghui , MIN, Xiaoshan , WANG, Zhulun
CPC classification number: C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
Abstract translation: 本文描述的是与抗原结合蛋白相关的组合物和方法，其结合人ST2，包括抗体。 在具体实施方案中，本公开提供完全人抗-ST2抗体及其衍生物和变体。 还提供了编码这种抗体和抗体片段，变体和衍生物的核酸。 此外，提供制备和使用这些抗体的方法，包括治疗和预防自身免疫性和炎症性疾病的方法。
-
7.发明申请
公开(公告)号：WO2022225921A1
公开(公告)日：2022-10-27
申请号：PCT/US2022/025340
申请日：2022-04-19
Applicant: AMGEN INC.
Inventor： GONG, Danyang , ESTES, Bram , WANG, Zhulun , GARCES, Fernando
Abstract: The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges particularly in regard to achieving acceptable expression levels free from mis-paired polypeptides. The presently claimed invention is directed to multispecific antigen binding proteins which improve upon existing charge pair technologies by redistributing the engineered charges within the CH3 regions of a heteromultimer.
-
公开(公告)号：WO2022103773A1
公开(公告)日：2022-05-19
申请号：PCT/US2021/058669
申请日：2021-11-09
Applicant: AMGEN INC.
Inventor： RILEY, Timothy , GARCES, Fernando , WANG, Zhulun , ESTES, Bram , BATES, Darren L.
IPC: C07K16/00
Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.
-
公开(公告)号：WO2022076474A2
公开(公告)日：2022-04-14
申请号：PCT/US2021/053650
申请日：2021-10-05
Applicant: AMGEN INC.
Inventor： GONG, Danyang , GARCES, Fernando , WANG, Zhulun
IPC: C07K16/00 , C12N15/09 , C07K2317/14 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/92
Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibody constructs, there are multiple modalities from which to choose and often multiple antigen binders as well. Described here is the discovery of new methods to optimally pair antigen binders with the proper format, including the selection of common light chains.
-
公开(公告)号：WO2022020636A2
公开(公告)日：2022-01-27
申请号：PCT/US2021/042836
申请日：2021-07-22
Applicant: AMGEN INC.
Inventor： GARCES, Fernando , WANG, Zhulun , RILEY, Timothy
IPC: A61K39/12 , C12N2770/20034
Abstract: The present invention relates to severe acute respiratory syndrome coronavirus 2 ("SARS-CoV2") immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2. The present invention also relates to methods of generating antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.024 seconds)
